Trial Profile
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 03 Aug 2020 Status changed from active, no longer recruiting to completed.
- 24 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 23 Oct 2013 New source identified and integrated (Oregon Health and Science University Institutional Review Board; IRB00008787).